For example, the detection of FGFR1 amplification has been associated with an increased risk of late recurrences in ER-positive BC [20], or PIK3CA mutations have been considered predictive of neoadjuvant chemotherapy resistance in HER2 positive BCs [16]. This evidence concerns the gene FGFR1 and breast cancer.